[{"data":1,"prerenderedAt":243},["ShallowReactive",2],{"$f5siocrxx0roj":3},{"schema":4,"slug":5,"series":6,"series_slug":7,"name":8,"year":9,"therapeutic_area":10,"generated_at":11,"counts":12,"top_targets":23,"top_modalities":55,"top_diseases":83,"top_companies":116,"key_results":142,"trends":231,"previous_editions":240,"comparison":147,"highlighted_classes":241},1,"acr-2026","ACR","acr","ACR Convergence 2026",2026,"Immunology","2026-11-05T22:19:09Z",{"abstracts":13,"drug_linked":14,"companies":15,"by_phase":16},2981,1025,208,{"Phase 1":17,"Phase 1\u002F2":18,"Phase 2":19,"Phase 4":20,"Phase 2\u002F3":21,"Phase 3":22},43,16,71,9,5,120,[24,28,32,35,39,41,44,47,50,53],{"name":25,"count":26,"share":27},"JAK1",81,8,{"name":29,"count":30,"share":31},"CD20",72,7,{"name":33,"count":34,"share":31},"CD19",69,{"name":36,"count":37,"share":38},"IL-17A",45,4,{"name":40,"count":17,"share":38},"GR",{"name":42,"count":43,"share":38},"TLR7",42,{"name":45,"count":46,"share":38},"Neuraminidase",41,{"name":48,"count":49,"share":38},"IFNAR1",40,{"name":51,"count":52,"share":38},"IL1R1",37,{"name":54,"count":52,"share":38},"TNFA",[56,60,63,67,70,73,77,81],{"name":57,"count":58,"share":59},"Small molecules",504,49,{"name":61,"count":62,"share":49},"Monoclonal antibodies",407,{"name":64,"count":65,"share":66},"Non-antibody therapeutic proteins",128,12,{"name":68,"count":69,"share":27},"Bispecific antibodies",86,{"name":71,"count":72,"share":31},"Cell therapies",67,{"name":74,"count":75,"share":76},"Peptides",29,3,{"name":78,"count":79,"share":80},"Vaccines",18,2,{"name":82,"count":18,"share":80},"Oligonucleotide and RNA therapeutics",[84,88,92,96,99,103,106,108,110,113],{"name":85,"count":86,"share":87},"systemic lupus erythematosus (SLE)",243,24,{"name":89,"count":90,"share":91},"rheumatoid arthritis (RA)",206,20,{"name":93,"count":94,"share":95},"psoriatic arthritis (PsA)",107,10,{"name":97,"count":98,"share":27},"systemic sclerosis (SSc)",79,{"name":100,"count":101,"share":102},"lupus nephritis (LN)",57,6,{"name":104,"count":105,"share":21},"anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV)",47,{"name":107,"count":43,"share":38},"interstitial lung disease (ILD)",{"name":109,"count":49,"share":38},"Sjögren's syndrome",{"name":111,"count":112,"share":38},"gout",39,{"name":114,"count":115,"share":38},"giant cell arteritis (GCA)",36,[117,120,122,125,127,130,133,135,138,140],{"name":118,"count":119,"share":102},"Pfizer",65,{"name":121,"count":101,"share":102},"Genentech",{"name":123,"count":124,"share":21},"Amgen",56,{"name":126,"count":59,"share":21},"Sanofi",{"name":128,"count":129,"share":38},"AbbVie",46,{"name":131,"count":132,"share":38},"GSK",44,{"name":134,"count":17,"share":38},"AstraZeneca",{"name":136,"count":137,"share":76},"Bayer",35,{"name":139,"count":137,"share":76},"Bristol Myers Squibb",{"name":141,"count":137,"share":76},"Johnson & Johnson",[143,151,158,165,173,181,187,194,202,210,218,224],{"title":144,"drug":145,"company":147,"phase":148,"disease":85,"finding":149,"url":150},"Combining Belimumab with Rituximab as a Treatment Strategy for Severe Systemic Lupus Erythematosus and Lupus Nephritis",{"name":146,"slug":146},"belimumab",null,"Phase 3","BEL\u002FRTX was superior with respect to the primary endpoint of treatment failure (HR 0.39 [0.19-0.77], p=0.005), with treatment failure occurring in 12 patients in the BEL\u002FRTX group versus 25 patients in the SoC group.","https:\u002F\u002Facrabstracts.org\u002Fabstract\u002Fcombining-belimumab-with-rituximab-as-a-treatment-strategy-for-severe-systemic-lupus-erythematosus-and-lupus-nephritis\u002F",{"title":152,"drug":153,"company":147,"phase":148,"disease":111,"finding":156,"url":157},"SSGJ-613 for the treatment of acute gout flares: results from a randomized, double-blind, double-dummy, active-controlled phase 3 trial",{"name":154,"slug":155},"SSGJ-613","ssgj-613","SSGJ-613 significantly delayed time to first new flare, and the risk of new flares was reduced by 77% compared with CB (HR: 0.23, 95% CI 0.17 to 0.32 ; P \u003C 0.0001) within 12 weeks.","https:\u002F\u002Facrabstracts.org\u002Fabstract\u002Fssgj-613-for-the-treatment-of-acute-gout-flares-results-from-a-randomized-double-blind-double-dummy-active-controlled-phase-3-trial\u002F",{"title":159,"drug":160,"company":147,"phase":148,"disease":162,"finding":163,"url":164},"Mepolizumab versus Conventional Therapy for Remission Induction in Eosinophilic Granulomatosis with Polyangiitis: Results from the Double-Blind, Double-Dummy, Randomized Controlled E-MERGE Trial",{"name":161,"slug":161},"mepolizumab","eosinophilic granulomatosis with polyangiitis (EGPA)","EGPA-related events occurred in 29.4% and 63.3% of patients, respectively (adjusted hazard ratio, 0.39; 95% CI, 0.21-0.72; P=0.003), mainly owing to fewer asthma and ENT exacerbations.","https:\u002F\u002Facrabstracts.org\u002Fabstract\u002Fmepolizumab-versus-conventional-therapy-for-remission-induction-in-eosinophilic-granulomatosis-with-polyangiitis-results-from-the-double-blind-double-dummy-randomized-controlled-e-merge-trial\u002F",{"title":166,"drug":167,"company":169,"phase":148,"disease":170,"finding":171,"url":172},"Efficacy and Safety of Sotatercept in Patients with Pulmonary Arterial Hypertension (PAH) Associated with CTD: A Pooled Analysis of Three Phase 3 Trials",{"name":168,"slug":168},"sotatercept","Merck","pulmonary arterial hypertension (PAH)","For major morbidity\u002Fmortality events, sotatercept reduced the risk of a first event versus placebo (HR 0.39 [95% CI: 0.19-0.83]; P=0.006), with 12 sotatercept-treated versus 25 placebo-treated participants having ≥1 event.","https:\u002F\u002Facrabstracts.org\u002Fabstract\u002Fefficacy-and-safety-of-sotatercept-in-patients-with-pulmonary-arterial-hypertension-pah-associated-with-ctd-a-pooled-analysis-of-three-phase-3-trials\u002F",{"title":174,"drug":175,"company":177,"phase":148,"disease":178,"finding":179,"url":180},"Nerandomilast in Idiopathic Inflammatory Myopathy-Associated Interstitial Lung Disease: Subgroup Analysis of the Phase III FIBRONEER™-ILD Trial",{"name":176,"slug":176},"nerandomilast","Boehringer Ingelheim","myositis-associated interstitial lung disease (MA-ILD)","Importantly, nerandomilast also reduced the risk of disease progression (key secondary endpoint) by 84% with the 9 mg dose (hazard ratio [HR]: 0.16; 95% CI 0.02 to 0.98) and 94% (HR: 0.06; 95% CI \u003C 0.01 to 0.61) with the 18 mg dose.","https:\u002F\u002Facrabstracts.org\u002Fabstract\u002Fnerandomilast-in-idiopathic-inflammatory-myopathy-associated-interstitial-lung-disease-subgroup-analysis-of-the-phase-iii-fibroneer-ild-trial\u002F",{"title":182,"drug":183,"company":134,"phase":148,"disease":85,"finding":185,"url":186},"Remission and Lupus Low Disease Activity State Attainment and Glucocorticoid Reduction without Increasing Flares with Anifrolumab in Asian patients with Systemic Lupus Erythematosus: A Post Hoc Analysis from a Phase III Study",{"name":184,"slug":184},"anifrolumab","Time to first attainment favored anifrolumab for DORIS (HR 3.18, 95% CI, 1.42 to 8.08) and LLDAS (HR 2.63, 95% CI, 1.77 to 3.99).","https:\u002F\u002Facrabstracts.org\u002Fabstract\u002Fremission-and-lupus-low-disease-activity-state-attainment-and-glucocorticoid-reduction-without-increasing-flares-with-anifrolumab-in-asian-patients-with-systemic-lupus-erythematosus-a-post-hoc-analys\u002F",{"title":188,"drug":189,"company":191,"phase":148,"disease":89,"finding":192,"url":193},"TARA: A Phase 3 Head-to-Head Trial of Girocitinib vs Tofacitinib in Patients with Active Rheumatoid Arthritis Refractory to bDMARDs",{"name":190,"slug":190},"girocitinib","Hangzhou Highlightll Pharmaceutical","The proportion of patients with serious adverse events (SAEs) was 3.9% in the girocitinib group and 6.6% in the tofacitinib group; treatment-related SAEs occurred in 1.3% and 2.6% of patients in girocitinib and tofacitinib groups, respectively.","https:\u002F\u002Facrabstracts.org\u002Fabstract\u002Ftara-a-phase-3-head-to-head-trial-of-girocitinib-vs-tofacitinib-in-patients-with-active-rheumatoid-arthritis-refractory-to-bdmards\u002F",{"title":195,"drug":196,"company":199,"phase":148,"disease":111,"finding":200,"url":201},"Efficacy and Safety of HR091506 Extended-Release Tablets Versus Febuxostat in Patients With Gout and Hyperuricemia: A Multicenter, Randomized, Double-Blind, Active-Controlled Phase 3 Trial",{"name":197,"slug":198},"HR091506","hr091506","Jiangsu HengRui Medicine Co., Ltd.","Over the 28-week treatment period, the incidences of treatment-emergent adverse events (TEAEs) were similar between groups (82.3% vs 83.9%), as were treatment-related TEAEs (54.2% vs 56.8%) and serious TEAEs (2.4% vs 3.6%).","https:\u002F\u002Facrabstracts.org\u002Fabstract\u002Fefficacy-and-safety-of-hr091506-extended-release-tablets-versus-febuxostat-in-patients-with-gout-and-hyperuricemia-a-multicenter-randomized-double-blind-active-controlled-phase-3-trial\u002F",{"title":203,"drug":204,"company":206,"phase":148,"disease":207,"finding":208,"url":209},"Envudeucitinib (ESK-001) in moderate-to-severe plaque psoriasis: 24-week results from the randomized, double-blind, active comparator- and placebo-controlled, Phase 3 ONWARD1 and 2 studies",{"name":205,"slug":205},"envudeucitinib","Alumis","plaque psoriasis","At Week 24, the most common AEs with envudeucitinib were headache (10.9%), nasopharyngitis (10.3%), acne (6.7%), and upper respiratory tract infection (6.4%).","https:\u002F\u002Facrabstracts.org\u002Fabstract\u002Fenvudeucitinib-esk-001-in-moderate-to-severe-plaque-psoriasis-24-week-results-from-the-randomized-double-blind-active-comparator-and-placebo-controlled-phase-3-onward1-and-2-studies\u002F",{"title":211,"drug":212,"company":214,"phase":148,"disease":215,"finding":216,"url":217},"Retatrutide Once Weekly for the Treatment of Knee Osteoarthritis Pain and Obesity: Results From a 68-Week Phase 3 Randomized Clinical Trial",{"name":213,"slug":213},"retatrutide","Eli Lilly","knee osteoarthritis (OA)","At W68, mean changes from baseline in WOMAC Pain subscale scores were -4.48 (RETA 9 mg), -4.41 (RETA 12 mg) and -2.43 (PBO); mean percent changes in BW were -26.4% (RETA 9 mg), -28.7% (RETA 12 mg) and -2.1% (PBO); p\u003C 0.001 vs PBO for all.","https:\u002F\u002Facrabstracts.org\u002Fabstract\u002Fretatrutide-once-weekly-for-the-treatment-of-knee-osteoarthritis-pain-and-obesity-results-from-a-68-week-phase-3-randomized-clinical-trial\u002F",{"title":219,"drug":220,"company":123,"phase":148,"disease":109,"finding":222,"url":223},"Dazodalibep Significantly Reduces Systemic Disease Activity in Patients with Sjögren’s Disease and Moderate-to-Severe Disease Activity: Results from the Phase 3 OASIZ-301 Trial",{"name":221,"slug":221},"dazodalibep","At W48, both dazodalibep regimens significantly improved ESSDAI vs PBO: LS mean change was −5.6 with 1500 mg Q4W (difference vs PBO, −1.8; adjusted p\u003C 0.001), −5.2 with 3000 mg Q12W (difference vs PBO, −1.4; adjusted p=0.010), and −3.8 with PBO.","https:\u002F\u002Facrabstracts.org\u002Fabstract\u002Fdazodalibep-significantly-reduces-systemic-disease-activity-in-patients-with-sjogrens-disease-and-moderate-to-severe-disease-activity-results-from-the-phase-3-oasiz-301-trial\u002F",{"title":225,"drug":226,"company":228,"phase":148,"disease":89,"finding":229,"url":230},"Comparison of Efficacy, Safety and Immunogenicity of DRL_AB (Proposed Abatacept Biosimilar) with Orencia® Administered by the Intravenous route as an Add-on to Methotrexate in Patients with Moderate to Severe Rheumatoid Arthritis: Results from a Randomized Double-Blind Study",{"name":227,"slug":147},"DRL_AB","Dr. Reddy's Laboratories","Related TEAEs were also comparable between DRL_AB (9.6%) and RMP (13.2%) over the entire study period.","https:\u002F\u002Facrabstracts.org\u002Fabstract\u002Fcomparison-of-efficacy-safety-and-immunogenicity-of-drl_ab-proposed-abatacept-biosimilar-with-orencia-administered-by-the-intravenous-route-as-an-add-on-to-methotrexate-in-patients-with-moder\u002F",{"summary":232,"bullets":234},[233],"Small molecules were the most frequent modality (49% of drug-linked abstracts). JAK1 was the most frequent target (8%). Systemic lupus erythematosus (SLE) was the most frequent disease (24%).",[235,236,237,238,239],"Pfizer had the largest company share (6% of drug-linked abstracts).","Bispecific antibodies accounted for 8% of drug-linked abstracts.","Monoclonal antibodies were the next most frequent modality (40%).","CD20 was the next most frequent target (7%).","Rheumatoid arthritis (RA) was the next most frequent disease (20%).",[],[242],{"name":68,"count":69,"share":27,"previous_count":147,"previous_share":147,"direction":147},1793970603084]